Bavarian Nordic Vaccine Helps Prolong Life in Prostate Cancer Trial

“An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute.

“Shares of Bavarian Nordic closed up almost 12 percent in Copenhagen after the company released the data on Tuesday.

“The study involved 30 patients with prostate cancer that had failed to benefit from standard treatments that reduce levels of testosterone, the male hormone that fuels the cancer.

“Patients were treated with the company’s Prostvac vaccine, in addition to escalating doses of Bristol-Myers Squibb Co’s Yervoy, an approved injectable treatment for advanced melanoma that works by taking the brakes off the body’s immune system.”